Jeffrey Smith
About Jeffrey Smith
Jeffrey Smith at Zymeworks
Jeffrey Smith joined Zymeworks in January 2023 as the Executive Vice President and Chief Medical Officer. He is based at the European hub in Dublin, Ireland. In his role, he is likely involved in overseeing medical strategies, guiding clinical development programs, and contributing to the company's overall mission in advancing therapeutic solutions.
Jeffrey Smith's Previous Experience at Alder Biopharmaceuticals
Before joining Zymeworks, Jeffrey Smith held significant positions at Alder Biopharmaceuticals Inc. He served as the Managing Director in Dublin, Ireland, where he managed the company's operations and strategic initiatives. In Seattle, he held the position of Senior Vice President, Translational Medicine, where he was responsible for overseeing the clinical development phases (I-III) of key therapeutic programs including eptinezumab for migraine and clazakizumab for rheumatoid arthritis and cancer cachexia.
Jeffrey Smith's Role in Clinical Development
Jeffrey Smith has played a crucial role in the clinical development of several important therapeutics. At Alder Biopharmaceuticals Inc., he was responsible for the clinical development phases I to III of eptinezumab, an anti-CGRP antibody for treating migraine, and clazakizumab, an anti-IL-6 antibody aimed at addressing rheumatoid arthritis and cancer cachexia. His work has significantly contributed to advancing these therapies through rigorous clinical trials.
Jeffrey Smith's Educational Background
Jeffrey Smith received his MB BS and MD from the University of London, UK. His educational background has laid a strong foundation for his subsequent roles in medical and clinical leadership. Additionally, he is a Fellow of the Royal College of Physicians in London, underscoring his commitment to high standards in the medical field.
Jeffrey Smith as Founder of Alder Biopharmaceuticals
Jeffrey Smith is the founder of Alder Biopharmaceuticals Inc., which was established in 2004. His visionary leadership and dedication to innovative therapeutic solutions were fundamental in shaping the company's growth and development. Under his guidance, Alder Biopharmaceuticals has embarked on various significant projects aimed at addressing unmet medical needs.